表紙
市場調査レポート

肥厚性瘢痕 : パイプライン分析

Hypertrophic Scars - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 277750
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
肥厚性瘢痕 : パイプライン分析 Hypertrophic Scars - Pipeline Review, H2 2015
出版日: 2015年11月18日 ページ情報: 英文 60 Pages
概要

肥厚性瘢痕は、皮膚損傷後の、皮膚組織の増殖が原因で起こります。症状は、厚く、赤みを帯びた傷跡(瘢痕)によって、痛みや痒みがもたらされます。肥厚は6ヶ月近くも保たれ、肥厚性瘢痕は1〜2年後に良くなる傾向があります。治療は、密封包帯、圧迫療法、病変内コルチコステロイド注射、凍結手術、切除術、放射線療法、レーザー療法、インターフェロン療法、コラーゲン合成など、あまり知られていない有望な治療法も含まれています。

当レポートでは、肥厚性瘢痕に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

肥厚性瘢痕の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • HanAll Biopharma Co., Ltd.
  • RXi Pharmaceuticals Corporation
  • Sirnaomics, Inc.
  • Symic Biomedical, Inc.
  • vida therapeutics inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • F06-C40
  • HL-156Fib
  • koebnerisin
  • Psoriasin
  • RXI-109
  • 創傷・瘢痕向け小分子
  • STP-705
  • V-2248
  • VTI-3000 シリーズ

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

  • Fibrostat
  • PF-06473871

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7382IDB

Summary

Global Markets Direct's, 'Hypertrophic Scars - Pipeline Review, H2 2015', provides an overview of the Hypertrophic Scars's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypertrophic Scars, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertrophic Scars and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypertrophic Scars
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypertrophic Scars and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypertrophic Scars products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypertrophic Scars pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypertrophic Scars
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypertrophic Scars pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypertrophic Scars Overview
  • Therapeutics Development
    • Pipeline Products for Hypertrophic Scars - Overview
    • Pipeline Products for Hypertrophic Scars - Comparative Analysis
  • Hypertrophic Scars - Therapeutics under Development by Companies
  • Hypertrophic Scars - Therapeutics under Investigation by Universities/Institutes
  • Hypertrophic Scars - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Hypertrophic Scars - Products under Development by Companies
  • Hypertrophic Scars - Products under Investigation by Universities/Institutes
  • Hypertrophic Scars - Companies Involved in Therapeutics Development
    • HanAll Biopharma Co., Ltd.
    • RXi Pharmaceuticals Corporation
    • Sirnaomics, Inc.
    • Symic Biomedical, Inc.
    • Vida Therapeutics Inc.
  • Hypertrophic Scars - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • F06-C40 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HL-156FIB - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • koebnerisin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • psoriasin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RXI-109 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Wounds and Scars - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • STP-705 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • V-2248 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VTI-3000 Series - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hypertrophic Scars - Recent Pipeline Updates
  • Hypertrophic Scars - Dormant Projects
  • Hypertrophic Scars - Discontinued Products
  • Hypertrophic Scars - Product Development Milestones
    • Featured News & Press Releases
      • Oct 15, 2015: RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109
      • Sep 28, 2015: RXi Pharmaceuticals Granted Patent in China for Lead Clinical Candidate RXI-109
      • Mar 23, 2015: RXi Pharmaceuticals Reports Positive Advancements in its Dermatology Programs at the Occasion of the 73rd Annual Meeting of the American Academy of Dermatology
      • Mar 11, 2015: RXi Pharmaceuticals to Present at the 73rd Annual Meeting of the American Academy of Dermatology
      • Jan 22, 2015: Sirnaomics Files to Begin Trial of Scar-healing Drug in China as it Seeks Funding in US
      • Jan 05, 2015: Sirnaomics and Partner Submit IND to CFDA
      • Oct 07, 2014: RXi Pharmaceuticals to Present New Data in its First Phase 2a Clinical Trial with RXI-109
      • Sep 18, 2014: RXi Pharmaceuticals to Present at the 7th Annual BioPharm America Conference
      • Sep 11, 2014: RXi Pharmaceuticals Presented an Update on the Company's Dermatology and Ophthalmology Franchises
      • Sep 03, 2014: RXi Pharmaceuticals to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypertrophic Scars, H2 2015
  • Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Hypertrophic Scars - Pipeline by HanAll Biopharma Co., Ltd., H2 2015
  • Hypertrophic Scars - Pipeline by RXi Pharmaceuticals Corporation, H2 2015
  • Hypertrophic Scars - Pipeline by Sirnaomics, Inc., H2 2015
  • Hypertrophic Scars - Pipeline by Symic Biomedical, Inc., H2 2015
  • Hypertrophic Scars - Pipeline by Vida Therapeutics Inc., H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Hypertrophic Scars Therapeutics - Recent Pipeline Updates, H2 2015
  • Hypertrophic Scars - Dormant Projects, H2 2015
  • Hypertrophic Scars - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Hypertrophic Scars, H2 2015
  • Number of Products under Development for Hypertrophic Scars - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top